Roche Diagnostics Makes Endotrophin Research Prototype Assay Available at Nordic Bioscience

Résumé détaillé
HERLEV, Denmark, Nov. 16, 2026 /PRNewswire/ -- Nordic Bioscience is pleased to announce that Roche Diagnostics is making its Endotrophin (ETP) research prototype assay available…
HERLEV, Denmark, Nov. 16, 2026 /PRNewswire/ -- Nordic Bioscience is pleased to announce that Roche Diagnostics is making its Endotrophin (ETP) research prototype assay available on its cobas® e801 Analyzers at Nordic Bioscience's CLIA lab.
The Endotrophin assay is a sandwich immunoassay that quantifies the intact 77-amino-acid Endotrophin hormone – the signaling pro-peptide released during formation of type VI collagen. Endotrophin is associated with fibrosis, inflammation and adverse outcomes across cardiovascular, kidney and metabolic disease.
Endotrophin is the second biomarker from the collaboration between Nordic Bioscience and Roche Diagnostics to reach the Roche platform, following the launch of Elecsys® PRO-C3, which is available as a CE-marked test.
Endotrophin has been measured in more than 50,000 patients with cardio-kidney-metabolic disease. Elevated Endotrophin levels have been associated with mortality and adverse outcomes in heart failure with preserved ejection fraction (HFpEF), and the FDA has issued a letter of support for the continued research of Endotrophin as a trial enrichment tool in HFpEF. Endotrophin captures fibroinflammatory risk beyond PREVENT and NT-proBNP[1]. In chronic kidney disease, Endotrophin levels are markedly increased with increasing disease activity; high levels predict eGFR decline, and changes in Endotrophin track changes in kidney function.
Endotrophin is more than a risk marker. Mendelian randomization studies link Endotrophin causally to coronary artery disease, knock-out models show protection against kidney fibrosis and loss of kidney function, and CD44 has been identified as the Endotrophin receptor.
"Endotrophin may be the best biomarker for the cardio-renal syndrome – but more importantly, it is more than a biomarker. It is a target to treat. We see it as a new TNF-alpha story," said Morten Karsdal, CEO of Nordic Bioscience.
[1] Yoshiji S, Osawa I, Hill JA, Scherer PE, Audoly L.
Nordic Bioscience is a Danish biomarker…
Début de l'article, extrait de PR Newswire. Pour lire la suite, ouvrez l'article chez le média.
MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.prnewswire.com)
